SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Novartis AG (NVSEF) trades at a trailing P/E of 20.9, forward P/E of 17.9. Trailing earnings yield is 4.79%, forward earnings yield 5.60%. PEG 0.76 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (75/100, Pass) — P/E is below market average (20.9); PEG ≤ 1.0 — Peter Lynch undervalued (0.76); earnings yield beats bond yields (4.79%).
- Forward P/E 17.9 (down from trailing 20.9) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.76 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 4.79% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 5.60% as earnings recover.
Overall SharesGrow Score: 73/100 with 5/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
75/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — NVSEF
Valuation Multiples
P/E (TTM)20.9
Forward P/E17.9
PEG Ratio0.76
Forward PEG1.06
P/B Ratio0.00
P/S Ratio5.36
EV/EBITDA0.0
Per Share Data
EPS (TTM)$7.49
Forward EPS (Est.)$8.75
Book Value / Share$0.00
Revenue / Share$29.22
FCF / Share$0.00
Yields & Fair Value
Earnings Yield4.79%
Forward Earnings Yield5.60%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$2.80 |
$49.44B |
$6.71B |
13.6% |
| 2017 |
$3.25 |
$50.14B |
$7.7B |
15.4% |
| 2018 |
$5.38 |
$53.17B |
$12.61B |
23.7% |
| 2019 |
$3.12 |
$48.68B |
$11.73B |
24.1% |
| 2020 |
$3.73 |
$49.9B |
$8.07B |
16.2% |
| 2021 |
$10.65 |
$52.88B |
$24.02B |
45.4% |
| 2022 |
$3.27 |
$51.83B |
$6.96B |
13.4% |
| 2023 |
$7.58 |
$46.66B |
$14.85B |
31.8% |
| 2024 |
$5.87 |
$51.72B |
$11.94B |
23.1% |
| 2025 |
$7.49 |
$57.13B |
$14.65B |
25.6% |
